Novel, non-nitrocatechol catechol-O-methyltransferase inhibitors modulate dopamine neurotransmission in the frontal cortex and improve cognitive flexibility.
Spencer ByersIngrid P BuchlerMichael DePasqualeHelen L RowleyRajiv S KulkarniLucy PinderAnna KolobovaCailian LiVinh AuDaniel AkumaGongliang ZhangHuijun WeiSharon C CheethamJames C BarrowGregory V CarrPublished in: Psychopharmacology (2020)
These results demonstrate that LIBD-1 is a novel COMT inhibitor with promising in vivo activity and the potential to serve as a new therapy for cognitive impairment.